Parabilis Medicines, Inc. (PBLS) SEC Filings

Parabilis Medicines, Inc. (PBLS) reports that Chief Medical Officer Fawzi Benzaghou, M.D. will transition from the company. The company and Dr. Benzaghou mutually agreed to his departure on August 28, 2026, with his service ending effective September 30, 2026.

In connection with this transition, Dr. Benzaghou is entitled to receive severance benefits in accordance with the terms of his existing employment agreement with Parabilis Medicines.

Parabilis Medicines, Inc. (PBLS) reported that director Craig Tendler received a grant of 20,294 stock options on August 22, 2026. The options carry an exercise price of $39.36 per share and expire on August 21, 2036. According to the grant terms, the options will vest in 36 equal monthly installments starting August 22, 2026, conditioned on Dr. Tendler’s continued service, resulting in post-transaction direct beneficial ownership of 20,294 derivative securities.

Parabilis Medicines, Inc. (symbol PBLS) reported the initial equity holdings of director Craig Tendler in a Form 3. Tendler holds a stock option to purchase 16,245 shares of Parabilis Medicines common stock at an exercise price of $2.42 per share, expiring on March 19, 2035.

According to the vesting terms, 25% of the shares subject to this option vested and became exercisable on January 31, 2026, with the remaining shares vesting in 36 equal monthly installments thereafter, subject to Tendler’s continued service on each vesting date.

Parabilis Medicines, Inc. (PBLS) expanded its Board of Directors to nine members and appointed Craig L. Tendler, M.D. as a Class II director, with his term running until the 2028 annual meeting of stockholders. The Board determined that he is independent under Nasdaq listing standards and named him to the Science & Technology Committee. As part of the non-employee director compensation program, he received a stock option to purchase 20,294 shares at an exercise price of $39.36 per share, vesting in 36 equal monthly installments over three years while he remains on the Board, plus annual cash retainers of $40,000 for Board service and $7,500 for Science & Technology Committee service, paid quarterly and pro rated. Parabilis highlighted Dr. Tendler’s more than 30 years of oncology drug development and medical affairs experience, including leadership roles at Johnson & Johnson contributing to over 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations and approvals for 15 New Molecular Entities, and positioned his expertise as complementary to its Helicon peptide platform and lead candidate zolucatetide.

Parabilis Medicines, Inc. has disclosed that ARCH Venture Fund XII, L.P. is the record holder of 6,412,780 shares of its Common Stock. Through a chain of general partners and an investment committee, ARCH Venture Partners XII, L.P., ARCH Venture Partners XII, LLC, and four committee members may be deemed to share voting and dispositive power over these shares.

The position represents 5.3% of the Common Stock class, based on 121,952,030 shares outstanding as of August 10, 2026. All reporting parties disclaim beneficial ownership beyond any shares they hold directly.

Parabilis Medicines, Inc., a clinical-stage biopharmaceutical company developing Helicon peptide therapeutics, reported its first results as a public company for the period ended June 30, 2026. In June, it completed an IPO of 38,525,000 common shares at $20.00 per share and a concurrent private placement of 4,166,666 shares to Regeneron at $18.00 per share, generating aggregate net proceeds of $787.9 million. In addition, Parabilis received a non-refundable $50.0 million upfront payment under its license and collaboration agreement with Regeneron.

These transactions lifted cash and cash equivalents to $1,087.1 million, marketable securities to $33.6 million, and total assets to $1,175.3 million as of June 30, 2026. For the six months ended June 30, 2026, Parabilis recorded collaboration revenue of $148 thousand, research and development expense of $77.1 million, general and administrative expense of $21.4 million, and a net loss of $97.8 million compared to $73.1 million in the prior-year period. The accumulated deficit was $639.3 million, but management states that existing cash, cash equivalents and marketable securities are expected to fund operations for at least twelve months from issuance.

Parabilis Medicines, Inc. reported second-quarter 2026 results and major strategic developments. The company closed an upsized initial public offering raising $770.5 million at $20.00 per share and completed a concurrent $75 million private placement with Regeneron. Parabilis ended June 30, 2026 with $1.1 billion in cash, cash equivalents and marketable securities, which it expects will fund operations into 2030.

Parabilis announced a strategic collaboration with Regeneron for Antibody-Helicon Conjugates, receiving $125 million in upfront and equity consideration and the potential for up to $2.2 billion in milestones plus tiered royalties. The lead Helicon, zolucatetide, is advancing toward a planned Phase 3 registrational trial in desmoid tumors in the first half of 2027, with additional clinical milestones in familial adenomatous polyposis, adamantinomatous craniopharyngioma and other Wnt/β‑catenin–driven tumors.

For the quarter ended June 30, 2026, collaboration revenue was $148,000. Research and development expenses were $39.4 million and general and administrative expenses were $11.7 million, leading to a net loss of $52.5 million versus $34.8 million a year earlier, primarily due to higher operating costs as programs and public-company infrastructure expanded.

FMR LLC filed a Schedule 13G reporting a passive ownership stake in Parabilis Medicines Inc. common stock. FMR LLC reports beneficial ownership of 10,292,735 shares, representing 8.5% of the outstanding common stock, with sole voting and sole dispositive power over these shares.

Abigail P. Johnson is also listed as a reporting person and is deemed to beneficially own the same 10,292,735 shares, or 8.5% of the class, with sole dispositive power and no voting power reported in her line item. One or more other persons have rights to receive dividends or sale proceeds related to these shares, but no such person holds more than five percent of the total outstanding common stock.

RA Capital-affiliated funds reported open-market purchases of 244,593 shares of Parabilis Medicines voting common stock from July 20–22, 2026, at weighted average prices around $27–30 per share. The shares are held indirectly by RA Capital Healthcare Fund LP, with the adviser and principals disclaiming beneficial ownership beyond their pecuniary interests.